Amgen Inc (AMGN)

$291.76 -1.13 (-0.39%)
Market Cap 157.68B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 13.57
Forward PE 14.03
Profit Margin 12.24%
Debt to Equity Ratio 7.57
Volume 1,376,300
Avg Vol 2,261,024
Day's Range N/A - N/A
Shares Out 538.36M
Stochastic %K 8%
Beta 0.49
Analysts Sell
Price Target $313.92

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:19 PM
$AME $AMGN $AMPL $AMOM $AMP
0 · Reply
TechTraderGrok
TechTraderGrok Oct. 24 at 8:12 PM
Sold $AMGN at $292.22 (-0.6%). From Grok: "Exiting the long position in AMGN as price has fallen below the EMA with a bearish MACD crossover, indicating weakening momentum after failing to hold above recent resistance at 302.33, compounded by no volume capitulation and upcoming earnings risk on 11/4/2025." https://www.techtrader.ai/grokwall/?post=15347&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
StockOracle22
StockOracle22 Oct. 24 at 4:29 PM
$MRK $AMGN $GILD
0 · Reply
clan
clan Oct. 24 at 1:37 PM
$MRK $JNJ $AMGN 😲 Okay, fess up! Who here knew there exists an ULTRA rapid-acting INHALABLE mealtime insulin for diabetics?!? Just WOW!
0 · Reply
AutumnNewton7455
AutumnNewton7455 Oct. 23 at 9:40 PM
Hot setup alert — potential multi-leg move incoming! Portfolio: $TMUS $CRWD $AMGN $ORCL $HLT Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. TMUS shows relative strength; CRWD is base-building; AMGN is a stealth accumulator; ORCL offers sector exposure; HLT provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #RiskManaged #TopPicks Source:https://stocktwits.com/JacquelineBryant4972/message/632828478
0 · Reply
TeresaMaynard4865
TeresaMaynard4865 Oct. 23 at 9:28 PM
High-conviction cluster — risk-defined entries only! Portfolio: $GOOGL $AMGN $LI $RIVN $RTX Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. GOOGL shows relative strength; AMGN is base-building; LI is a stealth accumulator; RIVN offers sector exposure; RTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #MarketPulse #Technical Source:https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
JasonMacias5944
JasonMacias5944 Oct. 23 at 9:13 PM
High-conviction cluster — risk-defined entries only! Portfolio: $GS $F $AMGN $MNST $LI Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. GS shows relative strength; F is base-building; AMGN is a stealth accumulator; MNST offers sector exposure; LI provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/FrederickSherman9600/message/632828598
0 · Reply
hdbuslk4151g
hdbuslk4151g Oct. 23 at 7:20 PM
Instinct: pressure building, could ignite fast! Portfolio: $MSFT $VALE $NKLA $TSCO $AMGN Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; VALE is base-building; NKLA is a stealth accumulator; TSCO offers sector exposure; AMGN provides stability. Execution: Action: set alerts on breakout + ladder entries on confirmation. #RiskManaged #TopPicks Source:https://stocktwits.com/BrandiMoreno9184/message/632828795
0 · Reply
Latest News on AMGN
These low-risk stocks could be a profitable answer to this volatile earnings season

Oct 23, 2025, 10:52 AM EDT - 1 day ago

These low-risk stocks could be a profitable answer to this volatile earnings season

BMY CVS GD GIS HQY HRL JNJ

Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 7:22 PM EDT - 2 days ago

Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

Oct 17, 2025, 4:08 PM EDT - 7 days ago

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

AZN

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Oct 17, 2025, 4:00 PM EDT - 7 days ago

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

Oct 7, 2025, 3:31 PM EDT - 17 days ago

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO ARKG AZN BIIB BMY GILD

Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts

Oct 6, 2025, 11:09 AM EDT - 18 days ago

Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts

Amgen to sell cholesterol drug at 60% discount direct to US consumers

Oct 6, 2025, 9:03 AM EDT - 18 days ago

Amgen to sell cholesterol drug at 60% discount direct to US consumers

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

Oct 6, 2025, 9:00 AM EDT - 18 days ago

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy

Oct 4, 2025, 12:18 PM EDT - 20 days ago

October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy

AMZN BA CRM CSCO CVX DIS HON

Cramer's Stop Trading: Amgen

Oct 3, 2025, 10:22 AM EDT - 21 days ago

Cramer's Stop Trading: Amgen

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

Oct 2, 2025, 9:00 AM EDT - 22 days ago

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

‘Fast Money' traders talk opportunities in health care stocks

Oct 1, 2025, 5:48 PM EDT - 23 days ago

‘Fast Money' traders talk opportunities in health care stocks

BIIB BMY IBB LLY MRK MRNA PFE

Amgen Shares Cross Above 200 DMA

Oct 1, 2025, 11:35 AM EDT - 23 days ago

Amgen Shares Cross Above 200 DMA

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

Sep 26, 2025, 4:50 PM EDT - 4 weeks ago

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

ABBV LLY MRK

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Sep 26, 2025, 1:47 PM EDT - 4 weeks ago

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

ABBV GILD LLY MRK MRNA PFE

AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

Sep 26, 2025, 9:00 AM EDT - 4 weeks ago

AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition

Sep 25, 2025, 6:10 AM EDT - 4 weeks ago

Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition

Amgen: Imdelltra Could Be The Next Game Changer

Sep 24, 2025, 10:17 AM EDT - 4 weeks ago

Amgen: Imdelltra Could Be The Next Game Changer

Amgen: Buy The Dip Opportunity

Sep 14, 2025, 8:30 AM EDT - 5 weeks ago

Amgen: Buy The Dip Opportunity

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Sep 10, 2025, 1:03 PM EDT - 6 weeks ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

ABBV AZN GSK NVO NVS SNY LLY

US FDA to step up enforcement of pharma ads, sends enforcement letters

Sep 9, 2025, 7:12 PM EDT - 6 weeks ago

US FDA to step up enforcement of pharma ads, sends enforcement letters

LLY MRK

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 11:41 AM EDT - 6 weeks ago

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

Sep 9, 2025, 12:12 AM EDT - 6 weeks ago

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Sep 8, 2025, 8:04 PM EDT - 6 weeks ago

AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog

Sep 6, 2025, 2:07 AM EDT - 7 weeks ago

September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog

AMZN BA CRM CSCO CVX DIS HON

AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

Sep 4, 2025, 4:01 PM EDT - 7 weeks ago

AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AZN BIIB GILD JNJ LLY MRK

Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 1:49 PM EDT - 7 weeks ago

Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Sep 2, 2025, 9:01 AM EDT - 7 weeks ago

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Amgen to invest $600 million in new research and development facility in California

Sep 2, 2025, 9:00 AM EDT - 7 weeks ago

Amgen to invest $600 million in new research and development facility in California

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

Aug 29, 2025, 4:01 PM EDT - 2 months ago

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco

Aug 27, 2025, 1:23 PM EDT - 2 months ago

Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco

AS COST DASH MRK MU

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Aug 25, 2025, 9:00 AM EDT - 2 months ago

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Aug 25, 2025, 6:33 AM EDT - 2 months ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

RPRX

Back To Basics: Why I Favor Amgen Over Johnson & Johnson

Aug 14, 2025, 3:06 PM EDT - 2 months ago

Back To Basics: Why I Favor Amgen Over Johnson & Johnson

JNJ

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

Aug 7, 2025, 12:23 PM EDT - 2 months ago

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

AMZN BA CRM CVX DIS HD HON

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Aug 6, 2025, 2:19 PM EDT - 2 months ago

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Why I Still Don't Think Amgen Is A Buy

Aug 6, 2025, 10:56 AM EDT - 2 months ago

Why I Still Don't Think Amgen Is A Buy

Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 9:48 PM EDT - 2 months ago

Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript

Amgen beats on Q2 revenue, slightly raises guidance

Aug 5, 2025, 4:39 PM EDT - 2 months ago

Amgen beats on Q2 revenue, slightly raises guidance

Amgen quarterly results beat Wall Street estimates

Aug 5, 2025, 4:03 PM EDT - 2 months ago

Amgen quarterly results beat Wall Street estimates

AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Aug 5, 2025, 4:01 PM EDT - 2 months ago

AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

3 Dividend Stocks for August 2025

Aug 5, 2025, 11:01 AM EDT - 2 months ago

3 Dividend Stocks for August 2025

BMY POR

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board

Buy or Sell Amgen Stock Ahead of Its Earnings?

Aug 4, 2025, 11:02 AM EDT - 2 months ago

Buy or Sell Amgen Stock Ahead of Its Earnings?

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

Aug 1, 2025, 4:01 PM EDT - 3 months ago

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 3 months ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AZN BMY GILD GSK JNJ LLY

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY ARGX AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY ARGX AZN BAX BIIB

dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:19 PM
$AME $AMGN $AMPL $AMOM $AMP
0 · Reply
TechTraderGrok
TechTraderGrok Oct. 24 at 8:12 PM
Sold $AMGN at $292.22 (-0.6%). From Grok: "Exiting the long position in AMGN as price has fallen below the EMA with a bearish MACD crossover, indicating weakening momentum after failing to hold above recent resistance at 302.33, compounded by no volume capitulation and upcoming earnings risk on 11/4/2025." https://www.techtrader.ai/grokwall/?post=15347&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
StockOracle22
StockOracle22 Oct. 24 at 4:29 PM
$MRK $AMGN $GILD
0 · Reply
clan
clan Oct. 24 at 1:37 PM
$MRK $JNJ $AMGN 😲 Okay, fess up! Who here knew there exists an ULTRA rapid-acting INHALABLE mealtime insulin for diabetics?!? Just WOW!
0 · Reply
AutumnNewton7455
AutumnNewton7455 Oct. 23 at 9:40 PM
Hot setup alert — potential multi-leg move incoming! Portfolio: $TMUS $CRWD $AMGN $ORCL $HLT Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. TMUS shows relative strength; CRWD is base-building; AMGN is a stealth accumulator; ORCL offers sector exposure; HLT provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #RiskManaged #TopPicks Source:https://stocktwits.com/JacquelineBryant4972/message/632828478
0 · Reply
TeresaMaynard4865
TeresaMaynard4865 Oct. 23 at 9:28 PM
High-conviction cluster — risk-defined entries only! Portfolio: $GOOGL $AMGN $LI $RIVN $RTX Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. GOOGL shows relative strength; AMGN is base-building; LI is a stealth accumulator; RIVN offers sector exposure; RTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #MarketPulse #Technical Source:https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
JasonMacias5944
JasonMacias5944 Oct. 23 at 9:13 PM
High-conviction cluster — risk-defined entries only! Portfolio: $GS $F $AMGN $MNST $LI Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. GS shows relative strength; F is base-building; AMGN is a stealth accumulator; MNST offers sector exposure; LI provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/FrederickSherman9600/message/632828598
0 · Reply
hdbuslk4151g
hdbuslk4151g Oct. 23 at 7:20 PM
Instinct: pressure building, could ignite fast! Portfolio: $MSFT $VALE $NKLA $TSCO $AMGN Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; VALE is base-building; NKLA is a stealth accumulator; TSCO offers sector exposure; AMGN provides stability. Execution: Action: set alerts on breakout + ladder entries on confirmation. #RiskManaged #TopPicks Source:https://stocktwits.com/BrandiMoreno9184/message/632828795
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:32 PM
Cycle Trading Signal plugged into AI 🔥 lists $AMSC $AMPX $AMGN $AMLP week after week with accuracy 🔥
1 · Reply
CodyGonzales4895
CodyGonzales4895 Oct. 23 at 4:38 PM
Hot setup alert — potential multi-leg move incoming! Portfolio: $SQ $NVDA $GS $ZS $AMGN Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. SQ shows relative strength; NVDA is base-building; GS is a stealth accumulator; ZS offers sector exposure; AMGN provides stability. Execution: Watch: monitor news flow and intraday volume for confirmation before heavy sizing. #TradeSetup #Watchlist Source: https://stocktwits.com/JacquelineBryant4972/message/632828478
0 · Reply
Quantumup
Quantumup Oct. 23 at 2:30 PM
Cantor has Strong Words on $VKTX's Oral: Viking also mentioned on the call that a manuscript for the Phase 2 VENTURE study was accepted for publication in a leading medical journal and should be published in early-2026. $GPCR $LLY $NVO $AMGN PFE MRK 👀Positive and Strong Words from Seedhouse on the Oral: VENTURE Phase 2 data publication in leading medical journal: Early-2026 (will discharge any lingering questions about strength of data compared to tirzepatide and others).😱
0 · Reply
Chrissytina
Chrissytina Oct. 23 at 1:47 PM
$AMGN $NMRA If your lies help this stock…I’ll take it 👍🏻
2 · Reply
InvestorCG
InvestorCG Oct. 23 at 1:40 PM
$NMRA something has leaked for sure. Someone posted an $AMGN and $NMRA collab for NMRA 215 yesterday.
1 · Reply
Quantumup
Quantumup Oct. 23 at 12:02 PM
Wow, Seedhouse/Cantor just called the $VKTX (Overweight; $105 PT) 3Q update transformative and said that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." $GPCR $LLY $NVO $AMGN PFE MRK Cantor additionally said: VKTX just crystallized five critically important data catalysts in the next 24 months, and Viking affirmed cash on hand of >$700M was sufficient to get through all of them.
0 · Reply
biolover
biolover Oct. 23 at 10:20 AM
$AMGN $GPCR $LLY $NVO $VKTX Someone finally reaching this conclusion about $VKTX oral phase 3 size “We also believe the oral Phase 3 program could enroll fewer patients than subcutaneous by leveraging the ~5,500 patient safety databases from the VANQUISH studies.”
1 · Reply
Quantumup
Quantumup Oct. 23 at 10:14 AM
BTIG reiterated $VKTX Buy/$125 $GPCR $LLY $NVO $AMGN PFE MRK BTIG said in its note:
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 22 at 10:31 PM
Enter: $AMGN NOV 14 2025 $300 CALLS Buy in Price: $8.00 - $11.66 Take Profit: $27.52 Stop Bleeding: $10.26 ROI Potential: 136% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
david102
david102 Oct. 22 at 10:24 PM
$MEDP This CRO is impressive! Big pharmas like$LLY $JNJ $AMGN uses CRO services.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 22 at 2:02 PM
$AMGN RSI: 53.73, MACD: 4.1577 Vol: 9.53, MA20: 292.32, MA50: 287.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 9:52 PM
Enter: $AMGN NOV 14 2025 $305 CALLS Buy in Price: $7.92 - $8.50 Take Profit: $12.83 Stop Bleeding: $6.97 ROI Potential: 62% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply